Algen Biotechnologies has entered a multi-target partnership with AstraZeneca aimed at speeding up the discovery of new therapeutic targets in immunology. The collaboration will leverage Algen’s AI-driven AlgenBrain™ platform, which uses advanced CRISPR gene modulation and functional genomics to decode complex chronic inflammatory diseases at a molecular level.
Under the agreement, Algen will lead preclinical drug discovery efforts, while AstraZeneca will obtain exclusive rights to develop and commercialize therapies against the selected targets. The deal includes an upfront payment to Algen and milestone-based payments that could total up to $555 million.
“We’re excited to collaborate with AstraZeneca to bring the power of our AI-driven functional genomics platform to decode complex chronic inflammatory conditions for drug discovery,” said Chun-Hao Huang, Ph.D., CEO and Co-Founder of Algen Biotechnologies. He emphasized that the partnership aims to combine Algen’s innovative technology with AstraZeneca’s expertise in clinical development to accelerate the creation of new therapies.
Jim Weatherall, Ph.D., Chief Data Scientist at AstraZeneca, highlighted the importance of AI and machine learning in identifying biologically relevant drug targets. He noted that Algen’s platform provides a powerful way to discover targets with strong translational potential in humans, which could lead to more effective medicines.
AlgenBrain™ works by analyzing billions of RNA changes in disease-relevant human cells and linking gene regulation to disease progression and therapeutic outcomes. This human biology-based approach is designed to improve the accuracy of early drug discovery and increase the likelihood of clinical success.
Christine Du, Chief Business Officer and Co-Founder of Algen, described the partnership as part of a broader trend toward data-driven, biology-first drug discovery. She explained that AlgenBrain™ continuously integrates experimental biology with AI to uncover actionable targets, aiming to usher in a new era of precision medicine across multiple therapeutic areas.
The collaboration reflects a growing commitment in the pharmaceutical industry to combine cutting-edge technology with deep biological insights to tackle challenging diseases more effectively.